End-of-day quote
Pakistan S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
577.4
PKR
|
+3.93%
|
|
+9.16%
|
+14.44%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9,945
|
16,907
|
20,762
|
23,906
|
22,624
|
26,733
|
Enterprise Value (EV)
1 |
9,326
|
16,200
|
19,350
|
21,404
|
21,785
|
25,855
|
P/E ratio
|
13.6
x
|
16.9
x
|
14.1
x
|
12.9
x
|
9.15
x
|
10.9
x
|
Yield
|
3.74%
|
2.42%
|
2.5%
|
3.19%
|
3.7%
|
5.95%
|
Capitalization / Revenue
|
1.33
x
|
1.87
x
|
1.94
x
|
1.84
x
|
1.43
x
|
1.35
x
|
EV / Revenue
|
1.24
x
|
1.79
x
|
1.81
x
|
1.65
x
|
1.38
x
|
1.31
x
|
EV / EBITDA
|
7.79
x
|
11.3
x
|
9.37
x
|
8.63
x
|
6.42
x
|
7.23
x
|
EV / FCF
|
32.1
x
|
52.8
x
|
23.5
x
|
18.3
x
|
-14.7
x
|
40.8
x
|
FCF Yield
|
3.12%
|
1.89%
|
4.25%
|
5.48%
|
-6.79%
|
2.45%
|
Price to Book
|
3.49
x
|
4.9
x
|
4.52
x
|
4.04
x
|
2.96
x
|
2.66
x
|
Nbr of stocks (in thousands)
|
52,983
|
52,983
|
52,983
|
52,983
|
52,983
|
52,983
|
Reference price
2 |
187.7
|
319.1
|
391.9
|
451.2
|
427.0
|
504.6
|
Announcement Date
|
4/5/19
|
4/21/20
|
4/1/21
|
3/28/22
|
4/14/23
|
4/9/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,503
|
9,048
|
10,698
|
13,001
|
15,816
|
19,766
|
EBITDA
1 |
1,197
|
1,435
|
2,066
|
2,480
|
3,392
|
3,576
|
EBIT
1 |
1,066
|
1,321
|
1,937
|
2,313
|
3,209
|
3,378
|
Operating Margin
|
14.21%
|
14.6%
|
18.1%
|
17.79%
|
20.29%
|
17.09%
|
Earnings before Tax (EBT)
1 |
1,066
|
1,369
|
1,999
|
2,436
|
3,445
|
3,359
|
Net income
1 |
732.2
|
1,001
|
1,474
|
1,856
|
2,473
|
2,448
|
Net margin
|
9.76%
|
11.06%
|
13.78%
|
14.28%
|
15.63%
|
12.38%
|
EPS
2 |
13.82
|
18.89
|
27.82
|
35.04
|
46.67
|
46.20
|
Free Cash Flow
1 |
290.9
|
306.7
|
822.7
|
1,172
|
-1,480
|
634.5
|
FCF margin
|
3.88%
|
3.39%
|
7.69%
|
9.02%
|
-9.36%
|
3.21%
|
FCF Conversion (EBITDA)
|
24.29%
|
21.37%
|
39.83%
|
47.27%
|
-
|
17.74%
|
FCF Conversion (Net income)
|
39.73%
|
30.65%
|
55.82%
|
63.14%
|
-
|
25.92%
|
Dividend per Share
2 |
7.019
|
7.721
|
9.800
|
14.37
|
15.81
|
30.00
|
Announcement Date
|
4/5/19
|
4/21/20
|
4/1/21
|
3/28/22
|
4/14/23
|
4/9/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
620
|
706
|
1,412
|
2,502
|
838
|
878
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
291
|
307
|
823
|
1,172
|
-1,480
|
634
|
ROE (net income / shareholders' equity)
|
28%
|
31.8%
|
36.7%
|
35.3%
|
36.4%
|
27.7%
|
ROA (Net income/ Total Assets)
|
18.2%
|
19.2%
|
21.3%
|
19.1%
|
20.7%
|
16.4%
|
Assets
1 |
4,016
|
5,201
|
6,924
|
9,712
|
11,925
|
14,898
|
Book Value Per Share
2 |
53.70
|
65.10
|
86.70
|
112.0
|
144.0
|
189.0
|
Cash Flow per Share
2 |
14.70
|
16.20
|
16.20
|
15.40
|
8.170
|
4.010
|
Capex
1 |
113
|
265
|
367
|
278
|
835
|
788
|
Capex / Sales
|
1.51%
|
2.92%
|
3.43%
|
2.14%
|
5.28%
|
3.98%
|
Announcement Date
|
4/5/19
|
4/21/20
|
4/1/21
|
3/28/22
|
4/14/23
|
4/9/24
|
|
1st Jan change
|
Capi.
|
---|
| +14.44% | 110M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|